After US FDA Advisors Unanimously Back First OTC Naloxone Proposal, Meeting On Second Not Needed

“Meeting is no longer needed,” agency states in announcement. The same committees’ unanimous recommendation during a meeting in February on Emergent’s sNDA for OTC sales of 4-mg naloxone nasal spray made a repeat for HRT’s NDA for 3-mg spray unnecessary.